Clinical Study

Clinical Impact of Prophylactic Antibiotic Treatment for Self-Expandable Metallic Stent Insertion in Patients with Malignant Colorectal Obstruction

Jong-Sun Kim,¹ Wan-Sik Lee,¹ Cho-Yun Chung,¹ Hyung-Chul Park,¹ Dae-Seong Myung,¹ Chan-Young Oak,¹ Mi-Young Kim,¹ Mi-Ok Jang,² Seung-Ji Kang,² Hee-Chang Jang,² Sung-Bum Cho,¹ Hyun-Soo Kim,¹ and Young-Eun Joo¹

¹Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
²Division of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea

Correspondence should be addressed to Young-Eun Joo; yejoo@chonnam.ac.kr

Received 6 November 2014; Revised 19 March 2015; Accepted 22 March 2015

Academic Editor: Philipp Lenz

Copyright © 2015 Jong-Sun Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The aim of this study was to determine the efficacy of prophylactic antibiotics (PA) for reducing the infectious complications and the potential risk factors responsible for the infectious complications after stent insertion for malignant colorectal obstruction. Methods. We performed a retrospective review of 224 patients who underwent self-expandable metallic stent (SEMS) insertion for malignant colorectal obstruction from May 2004 to December 2012. Results. There were 145 patients in the PA group and 79 in non-PA group. The CRP level in PA group was significantly higher than that in non-PA. Abdominal tenderness and mechanical ileus were significantly more frequent in PA group than those in non-PA. The frequency of post-SEMS insertion fever, systemic inflammatory response syndrome (SIRS), and bacteremia was not significantly different between PA and non-PA groups. In multivariate analysis, the CRP level was risk factor related to post-SEMS insertion SIRS. However, in propensity score matching analysis, there was no independent risk factor related to post-SEMS insertion fever, SIRS, and bacteremia. Conclusion. The use of PA in patients with malignant colorectal obstruction may be not effective to prevent the development of infectious complications after SEMS insertion.

1. Introduction

Colorectal cancer is one of the leading causes of cancer-associated morbidity and mortality in the world, and the incidence of colorectal cancer has been increasing rapidly, especially in Asia [1]. Up to 30% of patients with colorectal cancer can present with acute obstruction of large bowel at the time of diagnosis and require emergent colorectal surgery [2, 3]. Emergency colorectal surgery for acute obstruction is associated with an increased risk of morbidity and mortality in comparison with elective surgery.

Self-expandable metallic stent (SEMS) insertion has been known initially to be effective and safe for relief of malignant colorectal obstruction and has now gained acceptance, either as a palliative treatment or as a bridge to elective surgery [4–6]. Recently, SEMS insertion in malignant colorectal obstruction is recommended for patients with clinical symptoms and imaging evidence, as an alternative treatment to emergency surgery in patients with high risk of postoperative mortality and as palliative treatment according to the clinical guideline published by European Society of Gastrointestinal Endoscopy (ESGE) [7] and reviewed and endorsed by the Governing Board of American Society for Gastrointestinal Endoscopy (ASGE) [8]. However, SEMS insertion is not recommended as a bridge to elective surgery and prophylactic treatment [7, 8].

SEMS insertion has the potential to allow clean bowel preparation, clinical stabilization, and evaluation of the entire
Patients with SEMS insertion for colorectal obstruction from May 2004 to December 2012 (N = 278)

Excluded patients
- Patients with fever and/or SIRS before SEMS insertion (N = 31)
- Patients using antibiotics within 1 week before SEMS insertion (N = 23)

Patients suitable for intention-to-treat analysis (N = 224)

PA group (N = 145)
- Fever (N = 9)
- SIRS (N = 19)
- Bacteremia (N = 5)

Non-PA group (N = 79)
- Fever (N = 6)
- SIRS (N = 5)
- Bacteremia (N = 3)

Figure 1: Flow chart showing patient selection of the allocation of malignant colorectal obstruction. SEMS, self-expandable metallic stent; N, number; PA, prophylactic antibiotic; SIRS, systemic inflammatory response syndrome.

Colonoscopy procedure requires inflation of the bowel and can irritate the bowel wall during manipulation, which can enhance the transmural migration of intestinal microbial flora across the bowel wall and cause subsequent infectious complications. SEMS insertion may be prone to cause the infectious complications because of the increase of wall tension and mucosal trauma during procedure and after. Therefore, a significant number of clinicians recommend PA to prevent the infectious complications after stent insertion, especially when patients with colorectal cancer present with acute emergency obstruction [10]. Recently, the routine use of PA may be unnecessary before SEMS insertion because SEMS insertion did not induce significant bacteremia in colorectal obstruction [13]. However, the benefit of PA in preventing the infectious complications including fever, systemic inflammatory response syndrome (SIRS), bacteremia, and sepsis in patients receiving SEMS insertion is not well-documented. The aim of this study was to determine the efficacy of PA for reducing the infectious complications and the potential risk factors responsible for the infectious complications after SEMS insertion for malignant colorectal obstruction.

2. Methods

2.1. Patients. Two hundred and seventy-eight patients who had received a SEMS for malignant colorectal obstruction from May 2004 to December 2012 at Chonnam National University Hwasun Hospital (Jeonnam, Korea) were analyzed retrospectively (Figure 1). Among them, 31 patients with fever (body temperature over 38.0°C) and/or SIRS and 23 patients taking antibiotics within 1 week before the insertion of SEMS were excluded. A total of 224 patients were finally enrolled. 145 of 224 patients received antibiotics before the insertion of SEMS (PA group) and the remaining 79 patients did not receive PA (non-PA group) (Figure 1). Third generation cephalosporin (ceftriaxone sodium or cefotaxime sodium 2 gram two times per day, intravenous) and/or metronidazole (500 mg three times per day, intravenous) were used for prophylaxis at the time of admission before the insertion of SEMS. All the patients had overt clinical features of colorectal obstruction such as nausea, vomiting, abdominal pain, tenderness, abdominal distention, or failure to pass feces and gas. Colorectal obstruction was diagnosed clinically and radiologically. All the patients received abdominal X-ray, colonoscopy, and computed tomography (CT) to evaluate the stage of colorectal cancer and to check the site, degree,
and length of obstruction before the insertion of SEMS. This study was approved by the Institutional Review Board of Chonnam National University Hwasun Hospital (IRB number: CNUHH-2012-28).

2.2. Clinical Protocol. SEMS insertion was principally indicated for malignant colorectal obstruction corresponding to the criteria based on obstructive symptoms, colonoscopic findings, and abdominal CT as described previously. Informed consent with adequate explanation of stent insertion and possible complications was obtained from each patient. Under the fluoroscopic guidance, colonoscope (CF-240; Olympus, Tokyo, Japan) or 2-channel therapeutic endoscope (GIF-2T240; Olympus, Tokyo, Japan) was inserted to the level of the obstruction. The obstruction was passed with an endoscopic retrograde cholangiopancreatography catheter (MTW Endoskopie, Wesel, Germany). After passing through the obstruction, the catheter was advanced over the 0.038-inch angled or straight stiff-type guidewire (Glidewire; Terumo, Tokyo, Japan) to the proximal region of obstruction. The guidewire was removed and a contrast dye (Gastrografin; Schering, Berlin, Germany) was injected to delineate the length, site, and morphology of obstruction. The catheter was then replaced by the guidewire. SEMS delivery catheter was advanced over the guidewire and positioned through the obstruction. Upon the release of SEMS delivery catheter, stent deployment began proximally and progressed distally as monitored under endoscopic and fluoroscopic guidance. After the deployment of the SEMS, the delivery system and guidewire were removed. Stent insertion was performed by 1 of 2 endoscopists (Sung-Bum Cho, Wan-Sik Lee). The 3 types of SEMS including Hanaro stent (M.I. Tech. Korea Co. Ltd., Seoul, Korea), Bona stent (Standard Sci-Tech Inc., Seoul, Korea), and Niti-s stent (Taewoong Medical Co., Seoul, Korea) were used. According to the endoscopist’s preference and experience, stent type was chosen. Stent length was decided by allowing for more than 2 cm away from the distal and proximal margin of the obstructing lesion using fluoroscopy. The diameter and length of stent used were 20–22 mm and 6–12 cm, respectively. Immediately, 1 day, and 3 days after stent insertion, the patient underwent abdominal X-ray to access the position and location of stent. The obstruction was defined as a state with narrow stool caliber or the inability to pass only small amounts of liquid stool or gas, and total obstruction was decreased or absent bowel sounds or the inability to pass any stool or gas. The following variables were analyzed to compare between prophylactic antibiotics (PA) group and non-PA group: age, sex, body mass index, laboratory findings on admission, aims for stent insertion (preoperative versus palliative), degree of obstruction (total versus subtotal), presence of abdominal pain and abdominal tenderness, stent type (covered versus uncovered), stent length (<10 cm versus ≥10 cm), stent diameter (≤22 mm versus >22 mm), obstruction site, presence of mechanical ileus, presence of carcinomatosis peritonei, technical success, clinical success, and complications after SEMS insertion.

2.4. Endpoints. The primary endpoint was the comparison of the infectious complications after SEMS insertion in PA and non-PA groups. The secondary endpoint was the comparison of technical and clinical outcomes after SEMS insertion in PA and non-PA groups.

2.5. Statistical Analysis. All values are expressed as the means ± standard deviation (SD) and were analyzed by Student’s t-test. The categorical variables were analyzed by the χ² test and Fishers exact test. Univariate and multivariate Cox proportional hazards models were used to assess risk factors for post-SEMS infectious complications and to compute hazard ratios and their 95% confidence intervals. We made a propensity score using a logistic model. All variables that differed significantly when comparing 2 groups were included in the logistic model, with backward selection. The propensity score was then used to adjust for efficacy of PA on post-SEMS infectious complications in a multivariable Cox model. The Statistical Package for the Social Sciences (SPSS/PC+ 18.0, Chicago, IL, USA) was used for all analyses. A value of P < 0.05 was accepted as statistical significance.

3. Results

3.1. Baseline Characteristics of Patient. A total of 224 patients were enrolled in this study. 145 patients received PA before the insertion of SEEMS (PA group) and 79 patients did not receive PA (non-PA group) (Figure 1). The baseline characteristics of the patients in both groups are summarized in Table 1. Of these, 126 patients received SEEMS as bridge therapy before curative surgery and 98 patients received SEEMS as palliation in advanced disease. The mean CRP value of PA group was 4.6 ± 6.6, which was significantly higher than that of non-PA (P = 0.001). Symptoms or signs of complete obstruction...
Table 1: Comparison of clinical characteristics in PA versus non-PA groups.

| Characteristics                        | PA group (N = 145) | Non-PA group (N = 79) | P value |
|----------------------------------------|-------------------|-----------------------|---------|
| Age, years (mean ± SD)                 | 67.6 ± 11.7       | 65.0 ± 12.6           | 0.128   |
| Sex (male/female)                      | 94 (64.8%)/51 (35.2%) | 54 (68.4%)/25 (31.6%) | 0.659   |
| Body mass index (kg/m²)                | 21.6 ± 2.7        | 21.8 ± 2.7            | 0.538   |
| Aims (preoperative/palliative)         | 82 (56.6%)/63 (43.4%) | 44 (55.7%)/35 (44.3%) | 1.000   |
| Diabetes mellitus                      | 21 (14.5%)        | 11 (13.9%)            | 1.000   |
| WBC (×1000), (/mm³)                    | 8.1 ± 3.2         | 7.5 ± 2.7             | 0.198   |
| ANC (×1000), (/mm³)                    | 5.8 ± 3.0         | 5.2 ± 2.5             | 0.124   |
| CRP∗ (mg/dL)                           | 4.6 ± 6.6         | 2.4 ± 3.4             | 0.001   |
| Potassium (mEq/L)                      | 3.9 ± 0.5         | 3.9 ± 0.8             | 0.556   |
| Abdominal pain                         | 112 (77.2%)       | 54 (68.4%)            | 0.154   |
| Abdominal tenderness∗                  | 66 (45.5%)        | 22 (27.8%)            | 0.010   |
| Degree of obstruction (total/subtotal) | 42 (29.0%)/103 (71.0%) | 19 (24.1%)/60 (75.9%) | 0.530   |
| Mechanical ileus∗                      | 80 (55.2%)        | 24 (27.8%)            | <0.001  |
| Carcinomatosis peritonei               | 18 (12.4%)        | 7 (8.9%)              | 0.509   |
| Obstruction site                       |                   |                       | 0.857   |
| Ascending colon                        | 3 (2.1%)          | 2 (2.5%)              |         |
| Hepatic flexure                        | 8 (5.5%)          | 5 (6.3%)              |         |
| Transverse colon                       | 3 (2.1%)          | 0 (0.0%)              |         |
| Splenic flexure                        | 7 (4.8%)          | 5 (6.3%)              |         |
| Descending colon                       | 8 (5.5%)          | 5 (6.3%)              |         |
| Rectosigmoid colon                     | 116 (80.0%)       | 62 (78.5%)            |         |

PA, prophylactic antibiotics; N, number; WBC, white blood cell; ANC, absolute neutrophil count; CRP, C-reactive protein; ∗significantly different.

Table 2: Comparison of procedure-related outcomes in PA versus Non-PA groups.

| Characteristics                  | PA group (N = 145) | Non-PA group (N = 79) | P value |
|----------------------------------|-------------------|-----------------------|---------|
| Stent type (covered/uncovered)   | 62 (42.8%)/83 (57.2%) | 29 (36.7%)/50 (63.3%) | 0.397   |
| Stent length (<10 cm/≥10 cm)     | 99 (68.3%)/46 (31.7%) | 52 (65.8%)/27 (34.2%) | 0.766   |
| Stent diameter (≤22 mm/>22 mm)   | 63 (43.4%)/82 (56.6%) | 28 (35.4%)/51 (64.6%) | 0.244   |
| Technical success                | 139 (95.9%)       | 74 (93.7%)            | 0.524   |
| Clinical success                 | 142 (97.9%)       | 75 (94.9%)            | 0.240   |
| Complications                    |                   |                       |         |
| Perforation                      | 4 (2.8%)          | 2 (2.5%)              | 1.000   |
| Migration                        | 17 (11.7%)        | 8 (10.1%)             | 0.826   |
| Reobstruction                    | 13 (9.0%)         | 6 (7.6%)              | 0.807   |
| Fever                            | 9 (6.2%)          | 6 (7.6%)              | 0.781   |
| SIRS                             | 19 (13.1%)        | 5 (6.3%)              | 0.174   |
| Bacteremia/blood culture         | 5/96 (5.2%)       | 3/41 (7.3%)           | 0.696   |
| Time interval (hours) between symptom onset and stent insertion | 232.8 ± 200.2 | 233.1 ± 150.5 | 0.529 |

WBC, white blood cell; ANC, absolute neutrophil count; CRP, C-reactive protein; PA, prophylactic antibiotic; SIRS, systemic inflammatory response.

such as abdominal tenderness and mechanical ileus were significantly more frequent in PA group than those in non-PA (P = 0.010 and P < 0.001, resp.). The most common location of the obstruction in both groups was the rectosigmoid colon (80.0% in PA group, 78.5% in non-PA group). The distribution of the obstruction locations was similar in both groups. The degree of colon obstruction was not significantly different between PA and non-PA groups (P = 0.530).

3.2. Technical and Clinical Outcomes. The technical and clinical outcomes after SEMS insertion in both groups are summarized in Table 2. Technical success rate was 95.1% (213/224) and was similar in both groups (95.9% (139/145) in PA group, 93.7% (74/79) in non-PA group, P = 0.524). Clinical success rate was 96.9% (217/224) and was also similar in both groups (97.9% (142/145) in PA group, 94.9% (75/79) in non-PA group, P = 0.240). Complications as a result of
stent insertion, including perforation, migration, and reobstruction, were similar in both groups \( (P > 1.000, P = 0.826, \text{ and } P = 0.807, \text{ resp.}) \). Post-SEMS insertion fever and SIRS were developed in 15 (6.7%) and 24 (10.7%), respectively. Blood culture was performed in 137 patients. Among them, post-SEMS insertion bacteremia was developed in 8 (5.8%). All of fever, SIRS, and bacteremia occurred within 72 hours after SEMS insertion. The frequency of post-SEMS insertion fever, SIRS, and bacteremia was not significantly different between the PA and non-PA groups \( (P = 0.781, 0.174, \text{ and } 0.696, \text{ resp.}) \). There was no post-SEMS insertion sepsis in both groups. The time interval between symptom onset and SEMS insertion was not significantly different between the PA and non-PA groups \( (P = 0.529) \).

### 3.3. Risk Factors for Infectious Complications after SEMS Insertion

We used multivariate logistic regression analysis adjusted with PA, CRP, abdominal tenderness, and mechanical ileus as covariates to validate the independent risk factors related to post-SEMS insertion fever, SIRS and bacteremia. The CRP level was the risk factor related to post-SEMS insertion SIRS. However, any of these factors was not risk factor related to post-SEMS insertion fever and bacteremia (Table 3). As shown in Table 1, higher CRP level, abdominal tenderness, and mechanical ileus were significantly associated with patients received antibiotics before the insertion of SEMS. It means that both groups differ in some respects. Therefore, we built the propensity score-matched pairs between 2 groups to limit its selection bias. The propensity score included CRP, abdominal tenderness, and mechanical ileus. After propensity score matching, a total of 102 patients, 51 in the PA group and 51 in the non-PA group, were matched, and there was no significant difference in outcome of propensity score-matched post-SEMS insertion fever, SIRS, and bacteremia between 2 groups (Table 4).

### 3.4. Endpoints

**Primary Endpoint.** The frequency and risk factors of infectious complications (using a propensity score) after SEMS insertion were not significantly different between PA and non-PA groups.

**Secondary Endpoint.** The technical and clinical outcomes after SEMS insertion were similar in PA and non-PA groups.

### 4. Discussion

Acute luminal obstruction is one of the common presentations of colorectal cancer [2, 3, 19]. Emergency surgery is the traditional treatment of choice but is associated with high morbidity and mortality [2]. Colon SEMS are well recognized and commonly used for preoperative decompression and palliation in malignant colorectal obstruction. Numerous studies have demonstrated that colon SEMS insertion is safe and effective on short-term basis compared with surgical interventions [6, 11, 20–22]. According to the recent published clinical guideline, SEMS insertion in malignant colorectal obstruction is recommended for the patients with symptomatic and radiological evidence, as an alternative to emergency surgery and as a palliative treatment. However, SEMS insertion is not recommended as a bridge to elective surgery and prophylactic treatment [7, 8].

The variety of endoscopic procedures is generally considered a low risk for development of infectious complications [23–25]. Despite the low risk of development of infectious complications, complications can be fatal, and for this reason, many clinicians administer pre- or perioperative antibiotics to patients undergoing high-risk endoscopic procedures including esophageal dilation, variceal sclerotherapy, and endoscopic retrograde cholangiopancreatogram with biliary obstruction [26–28]. Colon SEMS insertion is expected to
have a higher risk of infectious complications than diagnostic colonoscopy because of the increase of wall tension and intestinal barrier damage causing bacterial translocation during the procedure and after [13, 29]. Therefore, colon SEMS insertion-related infection may occur under the following circumstances; use of contaminated equipment and accessories or spread of intestinal flora to bloodstream and adjacent tissues by mucosal injury as a result of the procedure. The prevention of infectious complications is the reason why many clinicians routinely prescribe a PA before stent insertion, especially the patients with total colonic obstruction [9]. In our study, many clinicians showed a tendency to prescribe a PA, if the patients had any symptoms or signs suggesting colon cancer obstruction, such as abdominal distension, abdominal tenderness, and presence of mechanical ileus and elevated CRP.

However, until now, little is known about the clinical impact of PA for reducing the infectious complications after stent insertion. The first aim of this study was whether the use of PA is effective to reduce the infectious complications after stent insertion. Contrary to expectations, the frequency of colon SEMS insertion-related fever, SIRS, and bacteremia was not significantly different between the PA and non-PA groups in our study. Also, previously, colorectal SEMS insertion was associated with a low rate of bacteremia, similar to that of diagnostic colonoscopy [13]. The next aim was to determine the potential risk factors of colon SEMS insertion-related fever, SIRS, and bacteremia. In multivariate analysis, the CRP level was only risk factor related to colon SEMS insertion-related SIRS, except for fever and bacteremia. However, patients of PA group showed higher CRP level, higher incidence of abdominal tenderness, and mechanical ileus than those of non-PA group. The propensity score included CRP, abdominal tenderness, and mechanical ileus. In propensity score matching analysis, there was no independent risk factor related to colon SEMS insertion-related fever, SIRS, and bacteremia. These results suggest that PA has limited value, if any, for reducing the incidence of infectious complications, and that the treatment of PA for SEMS insertion may be an unnecessary or immoderate treatment.

The inappropriate use of antibiotics is associated with an alteration in intestinal microflora in humans. This may result in ranging from mild diarrhea to Clostridium difficile-associated colitis-induced fever, abdominal pain, abdominal distention, leukocytosis, and life-threatening fulminant colitis causing hemorrhage and necrosis. Also, in light of current concerns regarding the development of antibiotics resistance and the lack of literature to support the decision of the clinicians to use antibiotics, it may be acceptable that patients undergoing colon SEMS insertion are not administered any pre-, peri-, or post procedure antibiotics treatment unless subsequent complications indicate that this is necessary.

However, our study has some limitations. First, the study design was retrospective and nonrandomized and selection biases were unavoidable. Thus, the propensity score matching analysis was used to reduce selection bias in our study. However, it remains the major concern of our study. Second, it was inevitable that the PA group was heterogenous. For these reasons, a large prospective, multicenter, randomized control trial evaluating the efficacy of PA in reducing the infectious complications after SEMS insertion for malignant colorectal obstruction is required to provide more definitive evidence. In conclusion, based on our retrospective study, the use of PA for colonic SEMS insertion in patients with malignant colorectal cancer obstruction has little or no influence on the prevention of febrile event and infectious complications.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Acknowledgment**

This study was supported by a grant (HCRI 14021-1) from Chonnam National University Hwasun Hospital Institute for Biomedical Science.

**References**

[1] I. Hyodo, H. Suzuki, K. Takahashi et al., “Present status and perspectives of colorectal cancer in Asia: colorectal cancer working group report in 30th Asia-Pacific cancer conference,” *Japanese Journal of Clinical Oncology*, vol. 40, no. 1, Article ID hyq125, pp. 138–143, 2010.

[2] U. Ohman, “Prognosis in patients with obstructing colorectal carcinoma,” *The American Journal of Surgery*, vol. 143, no. 6, pp. 742–747, 1982.

[3] G. T. Deans, Z. H. Krukowski, and S. T. Irwin, “Malignant obstruction of the left colon,” *British Journal of Surgery*, vol. 81, no. 9, pp. 1270–1276, 1994.

[4] T. H. Baron, “Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract,” *The New England Journal of Medicine*, vol. 344, no. 22, pp. 1681–1687, 2001.

[5] U. P. Khot, A. Wenk Lang, K. Murali, and M. C. Parker, “Systematic review of the efficacy and safety of colorectal stents,” *British Journal of Surgery*, vol. 89, no. 9, pp. 1096–1102, 2002.

[6] M. Gajendran, C. Umaphathy, J. Naras, and A. Gelrud, “Clinical outcomes of colonic stent in a tertiary care center,” *Gastroenterology Research and Practice*, vol. 2014, Article ID 138724, 7 pages, 2014.

[7] J. E. van Hooft, E. E. van Halsema, G. Vanbiervliet et al., “Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline,” *Endoscopy*, vol. 46, no. 11, pp. 990–1053, 2014.

[8] J. E. van Hooft, E. E. van Halsema, G. Vanbiervliet et al., “Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline,” *Gastrointestinal Endoscopy*, vol. 80, no. 5, pp. 747–761.e75, 2014.

[9] A. J. Small, N. Coelho-Prabhu, and T. H. Baron, “Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors,” *Gastrointestinal Endoscopy*, vol. 71, no. 3, pp. 560–572, 2010.

[10] J. E. Lopera and M. A. De Gregorio, “Fluoroscopic management of complications after colorectal stent placement,” *Gut and Liver*, vol. 4, supplement 1, pp. S9–S18, 2010.
[11] R. Cirocchi, E. Farinella, S. Trastulli et al., “Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and meta-analysis,” *Surgical Oncology*, vol. 22, no. 1, pp. 14–21, 2013.

[12] S. Banerjee, B. Shen, T. H. Baron et al., “Antibiotic prophylaxis for GI endoscopy,” *Gastrointestinal Endoscopy*, vol. 67, no. 6, pp. 791–798, 2008.

[13] Y. J. Chun, N. R. Yoon, J. M. Park et al., “Prospective assessment of risk of bacteremia following colorectal stent placement,” *Digestive Diseases and Sciences*, vol. 57, no. 4, pp. 1045–1049, 2012.

[14] “American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” *Critical Care Medicine*, vol. 20, no. 6, pp. 864–874, 1992.

[15] J. Soong and N. Soni, “Sepsis: recognition and treatment,” *Clinical Medicine*, vol. 12, no. 3, pp. 276–280, 2012.

[16] T. H. Baron, P. A. Dean, M. R. Yates III, C. Canon, and R. E. Koehler, “Expandable metal stents for the treatment of colonic obstruction: Techniques and outcomes,” *Gastrointestinal Endoscopy*, vol. 47, no. 3, pp. 277–286, 1998.

[17] G. Fernánández-Esparrach, J. M. Bordas, M. D. Giráldez et al., “Severe complications limit long-term clinical success of self-expanding metal stents in patients with obstructive colorectal cancer,” *The American Journal of Gastroenterology*, vol. 105, no. 5, pp. 1087–1093, 2010.

[18] V. Shrivastava, O. Tariq, R. Tiam, C. Nyhsen, and R. Marsh, “Palliation of obstructing malignant colonic lesions using self-expanding metal stents: a single-center experience,” *Cardiovascular and Interventional Radiology*, vol. 31, no. 5, pp. 931–936, 2008.

[19] L. E. J. Kyllonen, “Obstruction and perforation complicating colorectal carcinoma. An epidemiologic and clinical study with special reference to incidence and survival,” *Acta Chirurgica Scandinavica*, vol. 153, no. 10, pp. 607–614, 1987.

[20] L. E. Targownik, B. M. Spiegel, J. Sack et al., “Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis,” *Gastrointestinal Endoscopy*, vol. 60, no. 6, pp. 865–874, 2004.

[21] S. Sebastian, S. Johnston, T. Geoghegan, W. Torreggiani, and M. Buckley, “Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction,” *The American Journal of Gastroenterology*, vol. 99, no. 10, pp. 2051–2057, 2004.

[22] I. Keränen, A. Lepistö, M. Udd, J. Halttunen, and L. Kylänpää, “Stenting for malignant colorectal obstruction: a single-center experience with 101 patients,” *Surgical Endoscopy*, vol. 26, no. 2, pp. 423–430, 2012.

[23] V. A. Botoman and C. M. Surawicz, “Bacteremia with gastrointestinal endoscopic procedures,” *Gastrointestinal Endoscopy*, vol. 32, no. 5, pp. 342–346, 1986.

[24] J. H. Siegel, S. A. Berger, R. A. Sable, R. Ho, and W. S. Rosenthal, “Low incidence of bacteremia following endoscopic retrograde cholangiopancreatography (ERCP),” *The American Journal of Gastroenterology*, vol. 71, no. 5, pp. 465–468, 1979.

[25] M. H. Mellow and R. J. Lewis, “Endoscopy related bacteremia. Incidence of positive blood cultures after endoscopy of upper gastrointestinal tract,” *Archives of Internal Medicine*, vol. 136, no. 6, pp. 667–669, 1976.